-
Mashup Score: 4
While developing its first-in-class gastric cancer drug Vyloy, Astellas had to coordinate with another pharma giant to usher the precision med into the market.
Source: www.pharmavoice.comCategories: General Medicine News, PayerTweet
-
Mashup Score: 1The Dodgers’ World Series run brought attention to a rare disease. Annexon is stepping up to the plate. - 5 month(s) ago
The company is looking to score an FDA nod for its investigational therapy that targets a molecule linked to Guillain-Barré syndrome and other autoimmune diseases.
Source: www.pharmavoice.comCategories: General Medicine News, Rare DiseaseTweet-
⚾🔬 In the wake of the LA #Dodgers' #WorldSeries win, MVP Freddie Freeman's son was diagnosed with #GuillainBarreSyndrome. How close are we to a treatment for this rare autoimmune neurological disorder? https://t.co/rZQB94JcLH
-
-
Mashup Score: 0Will a Medicare boost propel digital therapeutics to the mainstream? - 7 month(s) ago
Digital therapeutics have languished in the background of traditional medicines for years, but a recent reimbursement push may have gotten the ball rolling.
Source: www.pharmavoice.comCategories: General Medicine News, Future of MedicineTweet-
Will a Medicare boost propel digital therapeutics to the mainstream? https://t.co/nglSmADP3x https://t.co/H81FcMOoUm
-
-
Mashup Score: 43Hold for PV100 2024 - 7 month(s) ago
News for pharmacy pros
Source: www.pharmavoice.comCategories: General Medicine News, CardiologistsTweet-
Honored to be named to the 2024 Pharmavoice 100 for the work done on behalf of patients suffering from cardiomyopathy. https://t.co/W1cDdSroJh
-
-
Mashup Score: 2FDA adcomm reform talks heat up - 8 month(s) ago
As the agency considers eliminating adcomm votes from the approval process, members vie to have their voices heard.
Source: www.pharmavoice.comCategories: General Medicine News, Rare DiseaseTweet-
RT @BrielmaierL: FDA adcomm reform talks heat up https://t.co/1xKa2bygiV via @PharmaVoice The FDA has 50 technical and scientific adcomms…
-
-
Mashup Score: 3After Amylyx drug failure, what’s next for ALS? - 1 year(s) ago
The company’s combo treatment Relyvrio was approved in 2022, but after failing a phase 3 trial, may be pulled from the market.
Source: www.pharmavoice.comCategories: General Medicine News, Rare DiseaseTweet-
RT @BrielmaierL: After Amylyx drug failure, what’s next for ALS? https://t.co/pTVyHDFFK3 via @PharmaVoice A review of the current landsca…
-
-
Mashup Score: 2This biotech aims to expand the CRISPR toolkit for more disease targets in the liver and brain - 1 year(s) ago
Arbor Biotechnologies is looking past CRISPR’s recent regulatory wins and into the next stage of gene editing.
Source: www.pharmavoice.comCategories: General Medicine News, Rare DiseaseTweet-
RT @BrielmaierL: This biotech aims to expand the CRISPR toolkit for more disease targets in the liver and brain https://t.co/6YvjTgNGBT vi…
-
-
Mashup Score: 5
“They have the money,” and they’re using it to influence drug development, according to the executive director of the IQVIA Institute for Human Data Science.
Source: www.pharmavoice.comCategories: General Medicine News, Rare DiseaseTweet-
RT @BrielmaierL: Patient groups have become a powerhouse in R&D. Here’s a look at their impact. https://t.co/9unNV9d0R4 via @PharmaVoice…
-
-
Mashup Score: 2The 2023 PharmaVoice 100 - 2 year(s) ago
This year’s honorees are influential and devoted leaders lifting the pillars of the industry to new heights.
Source: www.pharmavoice.comCategories: General Medicine News, Latest HeadlinesTweet-
💯 – we think so too! @PharmaVoice just named our CEO @_PeterKirk to their annual list of 100 life science leaders measurably impacting the industry. We’re grateful for the work of this year’s honorees + physicians globally who make good health possible. https://t.co/AFp0NnaGW1 https://t.co/ULUWMJCtcI
-
-
Mashup Score: 0The 2023 PharmaVoice 100 - 2 year(s) ago
This year’s honorees are influential and devoted leaders lifting the pillars of the industry to new heights.
Source: www.pharmavoice.comCategories: General Medicine News, Latest HeadlinesTweet-
💯 – we think so too! @PharmaVoice just named CEO @_PeterKirk their annual list of 100 life science leaders measurably impacting the industry. We’re grateful for the work of all of this year’s honorees and physicians globally who make good health possible.https://t.co/DaNfzMExkB https://t.co/qfo9SJzzE2
-
Our Chief Medical Officer, Tadaaki Taniguchi, shared his insights with @PharmaVoice on bringing our first-in-class #oncology precision medicine for gastric and gastroesophageal junction cancer to market. Read the interview here: https://t.co/uDspwPZLnm For U.S. audiences only https://t.co/lu5ArbIDOm